BPMC - Blueprint Medicines Corporation Stock Price, News & Analysis

$70.36 4.56 (6.93 %)
(As of 11/23/2017 08:01 AM ET)
Previous Close$65.80
Today's Range$64.94 - $71.34
52-Week Range$25.08 - $74.42
Volume324,300 shs
Average Volume430,033 shs
Market Capitalization$2.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.26

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation logoBlueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.


Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BPMC
CUSIPN/A

Debt

Debt-to-Equity Ratio0.02%
Current Ratio11.28%
Quick Ratio11.28%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.77 million
Price / Sales99.32
Cash FlowN/A
Price / CashN/A
Book Value$8.70 per share
Price / Book8.09

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($3.41)
Net Income$-72,490,000.00
Net Margins-437.83%
Return on Equity-43.11%
Return on Assets-34.38%

Miscellaneous

Employees106
Outstanding Shares39,200,000

Frequently Asked Questions for Blueprint Medicines Corporation (NASDAQ:BPMC)

What is Blueprint Medicines Corporation's stock symbol?

Blueprint Medicines Corporation trades on the NASDAQ under the ticker symbol "BPMC."

How were Blueprint Medicines Corporation's earnings last quarter?

Blueprint Medicines Corporation (NASDAQ:BPMC) issued its earnings results on Tuesday, October, 31st. The biotechnology company reported ($0.96) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.90) by $0.06. The biotechnology company had revenue of $8.07 million for the quarter, compared to the consensus estimate of $5.35 million. Blueprint Medicines Corporation had a negative return on equity of 43.11% and a negative net margin of 437.83%. Blueprint Medicines Corporation's revenue was up 31.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.62) EPS. View Blueprint Medicines Corporation's Earnings History.

When will Blueprint Medicines Corporation make its next earnings announcement?

Blueprint Medicines Corporation is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Blueprint Medicines Corporation.

Where is Blueprint Medicines Corporation's stock going? Where will Blueprint Medicines Corporation's stock price be in 2017?

9 equities research analysts have issued 12 month price targets for Blueprint Medicines Corporation's stock. Their predictions range from $33.19 to $90.00. On average, they expect Blueprint Medicines Corporation's stock price to reach $70.47 in the next twelve months. View Analyst Ratings for Blueprint Medicines Corporation.

What are Wall Street analysts saying about Blueprint Medicines Corporation stock?

Here are some recent quotes from research analysts about Blueprint Medicines Corporation stock:

  • 1. Cowen and Company analysts commented, "We maintain our BUY rating following the Q3/17 results. Histogenics reported zero revenue and a diluted net loss of $5.1M, compared to CG/ consensus of $6.5M/$6.3M net loss, and LPS of $(0.23), compared with CG/consensus estimate of $(0.29)/$(0.28). As anticipated, the Q3 call was largely uneventful as Histogenics awaits one-year data from the NeoCart Phase 3 clinical trial. Management noted that 65% of patients are now at the one-year mark and reiterated their expectation for one-year data to be announced in Q3/18." (11/10/2017)
  • 2. According to Zacks Investment Research, "Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. " (11/2/2017)
  • 3. Jefferies Group LLC analysts commented, "Utilizing its drug discovery platform, BPMC is well positioned to build a balanced pipeline of proprietary & partnered products for cancer/rare disease. Early Ph1 data suggests its two candidates (BLU-285 & BLU-554) are effective & differentiated from current limited tx options, supporting further development." (12/14/2016)

Who are some of Blueprint Medicines Corporation's key competitors?

Who are Blueprint Medicines Corporation's key executives?

Blueprint Medicines Corporation's management team includes the folowing people:

  • Daniel S. Lynch, Chairman of the Board (Age 59)
  • Jeffrey W. Albers, President, Chief Executive Officer, Director (Age 46)
  • Tracey L. Mccain, executive vice president and chief legal (Age 49)
  • Marion Dorsch Ph.D., Chief Scientific Officer (Age 52)
  • Michael Landsittel, Vice President, Finance (Age 45)
  • Anthony L. Boral M.D. Ph.D., Chief Medical Officer (Age 54)
  • Kathryn Haviland, Chief Business Officer (Age 41)
  • Alexis Borisy, Director (Age 45)
  • Lonnel Coats, Independent Director (Age 52)
  • George D. Demetri, Independent Director (Age 60)

When did Blueprint Medicines Corporation IPO?

(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns Blueprint Medicines Corporation stock?

Blueprint Medicines Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include TimesSquare Capital Management LLC (2.21%), Pictet Asset Management Ltd. (1.54%), Perceptive Advisors LLC (1.08%), Victory Capital Management Inc. (1.07%), Point72 Asset Management L.P. (0.81%) and Bank of New York Mellon Corp (0.45%). Company insiders that own Blueprint Medicines Corporation stock include Anthony L Boral, Christoph Lengauer, Daniel Lynch, Fmr Llc, Jeffrey W Albers, Kate Haviland, Kevin P Starr, Marion Dorsch, Mark J Levin and Rock Ventures Ii LP Third. View Institutional Ownership Trends for Blueprint Medicines Corporation.

Who sold Blueprint Medicines Corporation stock? Who is selling Blueprint Medicines Corporation stock?

Blueprint Medicines Corporation's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Sandia Holdings LLC, Point72 Asset Management L.P., Prudential Financial Inc., Strs Ohio, Perceptive Advisors LLC, First Trust Advisors LP and Russell Investments Group Ltd.. Company insiders that have sold Blueprint Medicines Corporation company stock in the last year include Anthony L Boral, Daniel Lynch, Jeffrey W Albers, Kate Haviland, Kevin P Starr, Marion Dorsch, Mark J Levin and Rock Ventures Ii LP Third. View Insider Buying and Selling for Blueprint Medicines Corporation.

Who bought Blueprint Medicines Corporation stock? Who is buying Blueprint Medicines Corporation stock?

Blueprint Medicines Corporation's stock was purchased by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Pictet Asset Management Ltd., Alyeska Investment Group L.P., Ameriprise Financial Inc., Sei Investments Co., Jane Street Group LLC, Cornerstone Capital Management Holdings LLC. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Blueprint Medicines Corporation.

How do I buy Blueprint Medicines Corporation stock?

Shares of Blueprint Medicines Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Blueprint Medicines Corporation's stock price today?

One share of Blueprint Medicines Corporation stock can currently be purchased for approximately $70.36.

How big of a company is Blueprint Medicines Corporation?

Blueprint Medicines Corporation has a market capitalization of $2.58 billion and generates $27.77 million in revenue each year. The biotechnology company earns $-72,490,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis. Blueprint Medicines Corporation employs 106 workers across the globe.

How can I contact Blueprint Medicines Corporation?

Blueprint Medicines Corporation's mailing address is 38 SIDNEY STREET SUITE 200, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]


MarketBeat Community Rating for Blueprint Medicines Corporation (BPMC)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Blueprint Medicines Corporation (NASDAQ:BPMC)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $70.47 (0.15% upside)

Consensus Price Target History for Blueprint Medicines Corporation (NASDAQ:BPMC)

Price Target History for Blueprint Medicines Corporation (NASDAQ:BPMC)

Analysts' Ratings History for Blueprint Medicines Corporation (NASDAQ:BPMC)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/6/2017WedbushReiterated RatingOutperform$70.00 -> $82.00N/AView Rating Details
11/1/2017Canaccord GenuityReiterated RatingBuy$66.00 -> $80.00N/AView Rating Details
10/23/2017Morgan StanleyBoost Price TargetOverweight$45.00 -> $78.00N/AView Rating Details
9/29/2017DA DavidsonInitiated CoverageBuy$90.00HighView Rating Details
9/29/2017BTIG ResearchInitiated CoverageBuy -> Buy$90.00HighView Rating Details
9/20/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$64.00 -> $79.00LowView Rating Details
9/5/2017Jefferies Group LLCReiterated RatingBuy$56.00MediumView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageOutperform$37.00 -> $46.00LowView Rating Details
5/27/2016Raymond James Financial, Inc.Initiated CoverageOutperform$23.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$54.00 -> $37.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Blueprint Medicines Corporation (NASDAQ:BPMC)

Earnings by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Earnings History by Quarter for Blueprint Medicines Corporation (NASDAQ BPMC)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018        
10/31/2017Q3 2017($0.90)($0.96)$5.35 million$8.07 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.75)($0.86)$5.96 million$5.89 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.73)($0.84)$6.02 million$5.84 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.76)($0.75)$6.31 million$7.69 millionViewListenView Earnings Details
11/10/2016Q316($0.77)($0.62)$6.06 million$6.16 millionViewListenView Earnings Details
8/9/2016Q216($0.73)($0.70)$4.41 million$7.07 millionViewListenView Earnings Details
5/10/2016Q116($0.70)($0.57)$3.24 million$6.90 millionViewListenView Earnings Details
3/11/2016Q415($0.53)($0.58)$2.85 million$4.64 millionViewN/AView Earnings Details
11/9/2015Q3($0.54)($0.47)$1.83 million$3.43 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Blueprint Medicines Corporation (NASDAQ:BPMC)
2017 EPS Consensus Estimate: ($3.40)
2018 EPS Consensus Estimate: ($4.03)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.72)($0.72)($0.72)
Q2 20172($0.75)($0.75)($0.75)
Q3 20172($0.92)($0.90)($0.91)
Q4 20172($1.06)($0.98)($1.02)
Q1 20181($0.83)($0.83)($0.83)
Q2 20181($0.88)($0.88)($0.88)
Q3 20181($1.03)($1.03)($1.03)
Q4 20181($1.29)($1.29)($1.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Blueprint Medicines Corporation (NASDAQ:BPMC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Blueprint Medicines Corporation (NASDAQ BPMC)

Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 91.99%
Insider Trades by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)
Institutional Ownership by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Insider Trades by Quarter for Blueprint Medicines Corporation (NASDAQ BPMC)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/21/2017Marion DorschInsiderSell18,334$65.45$1,199,960.30View SEC Filing  
11/15/2017Daniel LynchDirectorSell5,000$63.38$316,900.00View SEC Filing  
11/6/2017Anthony L BoralInsiderSell5,000$70.40$352,000.00View SEC Filing  
11/6/2017Jeffrey W AlbersCEOSell30,000$70.31$2,109,300.00View SEC Filing  
10/5/2017Kate HavilandInsiderSell5,449$66.44$362,031.56View SEC Filing  
9/18/2017Daniel LynchDirectorSell2,500$60.00$150,000.00View SEC Filing  
9/18/2017Kate HavilandInsiderSell6,356$60.03$381,550.68View SEC Filing  
8/9/2017Anthony L BoralInsiderSell5,000$48.60$243,000.00View SEC Filing  
8/8/2017Jeffrey W AlbersCEOSell30,000$49.62$1,488,600.00View SEC Filing  
8/7/2017Jeffrey W AlbersCEOSell20,000$49.08$981,600.00View SEC Filing  
7/5/2017Daniel LynchDirectorSell7,500$55.06$412,950.00View SEC Filing  
7/5/2017Kate HavilandInsiderSell7,265$54.66$397,104.90View SEC Filing  
6/28/2017Daniel LynchDirectorSell32,500$50.28$1,634,100.00View SEC Filing  
6/28/2017Jeffrey W AlbersCEOSell20,000$50.47$1,009,400.00View SEC Filing  
6/28/2017Kate HavilandInsiderSell6,357$50.00$317,850.00View SEC Filing  
3/16/2017Mark J LevinMajor ShareholderSell30,000$40.88$1,226,400.00View SEC Filing  
2/7/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell1,000,000$35.28$35,280,000.00View SEC Filing  
12/19/2016Kevin P. StarrMajor ShareholderSell106,489$28.19$3,001,924.91View SEC Filing  
12/1/2016Daniel LynchDirectorSell200$30.02$6,004.00View SEC Filing  
10/13/2016Daniel LynchDirectorSell21,800$30.02$654,436.00View SEC Filing  
8/8/2016Jeffrey W AlbersCEOSell17,000$22.86$388,620.00View SEC Filing  
6/3/2016Jeffrey W AlbersCEOSell17,000$20.03$340,510.00View SEC Filing  
4/13/2016Christoph LengauerInsiderSell15,872$20.01$317,598.72View SEC Filing  
4/12/2016Christoph LengauerInsiderSell18,853$20.14$379,699.42View SEC Filing  
4/6/2016Jeffrey W AlbersCEOSell17,000$20.42$347,140.00View SEC Filing  
12/17/2015Christoph LengauerinsiderSell31,119$25.05$779,530.95View SEC Filing  
11/27/2015Fmr LlcInsiderSell287,415$21.48$6,173,674.20View SEC Filing  
11/24/2015Fmr LlcInsiderSell161,271$20.14$3,247,997.94View SEC Filing  
11/23/2015Fmr LlcInsiderSell189,572$20.15$3,819,875.80View SEC Filing  
11/19/2015Fmr LlcInsiderSell237,218$19.76$4,687,427.68View SEC Filing  
11/17/2015Fmr LlcInsiderSell27,490$20.60$566,294.00View SEC Filing  
11/3/2015Christoph LengauerinsiderSell84,998$21.05$1,789,207.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Blueprint Medicines Corporation (NASDAQ BPMC)

Source:
DateHeadline
Blueprint Medicines Corporation (BPMC) Insider Marion Dorsch Sells 18,334 SharesBlueprint Medicines Corporation (BPMC) Insider Marion Dorsch Sells 18,334 Shares
www.americanbankingnews.com - November 22 at 7:57 PM
Blueprint Medicines Corporation (BPMC) Director Daniel Lynch Sells 5,000 SharesBlueprint Medicines Corporation (BPMC) Director Daniel Lynch Sells 5,000 Shares
www.americanbankingnews.com - November 17 at 8:37 PM
Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : November 15, 2017Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : November 15, 2017
finance.yahoo.com - November 16 at 12:08 PM
Featured Company News - Blueprint Medicines Announced New Data from Ongoing Phase-1 Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal TumorsFeatured Company News - Blueprint Medicines Announced New Data from Ongoing Phase-1 Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors
finance.yahoo.com - November 14 at 5:08 PM
Blueprint Medicines Corporation (BPMC) Stock Rating Reaffirmed by Cowen and CompanyBlueprint Medicines Corporation (BPMC) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - November 10 at 7:38 PM
Blueprint Medicines (BPMC) Reports New Data from Ongoing Phase 1 Clinical Trial of BLU-285Blueprint Medicines (BPMC) Reports New Data from Ongoing Phase 1 Clinical Trial of BLU-285
www.streetinsider.com - November 10 at 4:16 PM
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRα GenotypesBlueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes
finance.yahoo.com - November 10 at 12:41 PM
Blueprint Medicines to Present at Jefferies Global Healthcare ConferenceBlueprint Medicines to Present at Jefferies Global Healthcare Conference
www.bizjournals.com - November 8 at 7:26 PM
Insider Selling: Blueprint Medicines Corporation (BPMC) Insider Sells 5,000 Shares of StockInsider Selling: Blueprint Medicines Corporation (BPMC) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - November 8 at 7:16 PM
Insider Selling: Blueprint Medicines Corporation (BPMC) CEO Sells 30,000 Shares of StockInsider Selling: Blueprint Medicines Corporation (BPMC) CEO Sells 30,000 Shares of Stock
www.americanbankingnews.com - November 8 at 6:30 PM
Blueprint Medicines Corporation (BPMC) & Alkermes PLC (ALKS) Financial ReviewBlueprint Medicines Corporation (BPMC) & Alkermes PLC (ALKS) Financial Review
www.americanbankingnews.com - November 8 at 2:28 PM
Blueprint Medicines Corporation (BPMC) Expected to Earn Q4 2017 Earnings of ($1.06) Per ShareBlueprint Medicines Corporation (BPMC) Expected to Earn Q4 2017 Earnings of ($1.06) Per Share
www.americanbankingnews.com - November 8 at 1:40 PM
Blueprint Medicines Corporation (BPMC) Expected to Post Quarterly Sales of $4.32 MillionBlueprint Medicines Corporation (BPMC) Expected to Post Quarterly Sales of $4.32 Million
www.americanbankingnews.com - November 7 at 5:52 AM
ETFs with exposure to Blueprint Medicines Corp. : November 6, 2017ETFs with exposure to Blueprint Medicines Corp. : November 6, 2017
finance.yahoo.com - November 6 at 5:47 PM
Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 5:19 PM
Zacks Investment Research Downgrades Blueprint Medicines Corporation (BPMC) to SellZacks Investment Research Downgrades Blueprint Medicines Corporation (BPMC) to Sell
www.americanbankingnews.com - November 2 at 8:33 PM
Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and ExpositionBlueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition
finance.yahoo.com - November 1 at 5:21 PM
Blueprint Medicines Announces Publication of BLU-285 Translational DataBlueprint Medicines Announces Publication of BLU-285 Translational Data
finance.yahoo.com - November 1 at 5:21 PM
Blueprint Medicines Corp (BPMC) Given "Buy" Rating at Canaccord GenuityBlueprint Medicines Corp (BPMC) Given "Buy" Rating at Canaccord Genuity
www.americanbankingnews.com - November 1 at 11:11 AM
Blueprint Medicines (BPMC) CEO Jeff Albers on Q3 2017 Results - Earnings Call TranscriptBlueprint Medicines' (BPMC) CEO Jeff Albers on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 31 at 10:51 PM
Edited Transcript of BPMC earnings conference call or presentation 31-Oct-17 12:30pm GMTEdited Transcript of BPMC earnings conference call or presentation 31-Oct-17 12:30pm GMT
finance.yahoo.com - October 31 at 10:51 PM
Blueprint Medicines Reports Third Quarter 2017 Financial ResultsBlueprint Medicines Reports Third Quarter 2017 Financial Results
finance.yahoo.com - October 31 at 5:50 PM
Blueprint Medicines reports 3Q lossBlueprint Medicines reports 3Q loss
finance.yahoo.com - October 31 at 5:50 PM
Blueprint Medicines Corporation (BPMC) Given "Buy" Rating at Cowen and CompanyBlueprint Medicines Corporation (BPMC) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - October 31 at 2:48 PM
Blueprint Medicines Corporation (BPMC) Posts Quarterly  Earnings ResultsBlueprint Medicines Corporation (BPMC) Posts Quarterly Earnings Results
www.americanbankingnews.com - October 31 at 8:52 AM
ETFs with exposure to Blueprint Medicines Corp. : October 25, 2017ETFs with exposure to Blueprint Medicines Corp. : October 25, 2017
finance.yahoo.com - October 25 at 6:11 PM
Blueprint Medicines Corporation (BPMC) Set to Announce Earnings on TuesdayBlueprint Medicines Corporation (BPMC) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 25 at 9:36 AM
Blueprint Medicines to Report Third Quarter 2017 Financial Results on Tuesday, October 31, 2017Blueprint Medicines to Report Third Quarter 2017 Financial Results on Tuesday, October 31, 2017
finance.yahoo.com - October 24 at 6:45 PM
 Analysts Anticipate Blueprint Medicines Corporation (BPMC) Will Announce Quarterly Sales of $5.16 Million Analysts Anticipate Blueprint Medicines Corporation (BPMC) Will Announce Quarterly Sales of $5.16 Million
www.americanbankingnews.com - October 18 at 7:20 AM
Blueprint Medicines Corporation (BPMC) Lifted to Hold at Zacks Investment ResearchBlueprint Medicines Corporation (BPMC) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - October 16 at 8:10 PM
Zacks: Brokerages Anticipate Blueprint Medicines Corporation (BPMC) Will Post Earnings of -$0.90 Per ShareZacks: Brokerages Anticipate Blueprint Medicines Corporation (BPMC) Will Post Earnings of -$0.90 Per Share
www.americanbankingnews.com - October 16 at 12:30 PM
Commit To Purchase Blueprint Medicines Corp At $50, Earn 15.4% Annualized Using OptionsCommit To Purchase Blueprint Medicines Corp At $50, Earn 15.4% Annualized Using Options
www.nasdaq.com - October 13 at 10:23 PM
BPMC Crosses Above Average Analyst TargetBPMC Crosses Above Average Analyst Target
www.nasdaq.com - October 11 at 6:11 PM
Kate Haviland Sells 5,449 Shares of Blueprint Medicines Corporation (BPMC) StockKate Haviland Sells 5,449 Shares of Blueprint Medicines Corporation (BPMC) Stock
www.americanbankingnews.com - October 10 at 7:38 PM
Blueprint Medicines Corporation (BPMC) Given Consensus Rating of "Buy" by BrokeragesBlueprint Medicines Corporation (BPMC) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 4 at 9:16 AM
Your Daily Pharma Scoop: Alexions Canada Pricing, Zogenix, RedHill, FlexionYour Daily Pharma Scoop: Alexion's Canada Pricing, Zogenix, RedHill, Flexion
seekingalpha.com - October 2 at 1:52 PM
Blueprint Medicines Corporation (BPMC) Now Covered by DA DavidsonBlueprint Medicines Corporation (BPMC) Now Covered by DA Davidson
www.americanbankingnews.com - September 29 at 10:03 AM
Blueprint Medicines Corporation (BPMC) Coverage Initiated at BTIG ResearchBlueprint Medicines Corporation (BPMC) Coverage Initiated at BTIG Research
www.americanbankingnews.com - September 29 at 9:08 AM
Blueprint Medicines Corporation (BPMC) Expected to Announce Earnings of -$0.90 Per ShareBlueprint Medicines Corporation (BPMC) Expected to Announce Earnings of -$0.90 Per Share
www.americanbankingnews.com - September 27 at 8:22 PM
Blueprint Medicines Corporation (BPMC) Price Target Increased to $66.00 by Analysts at Canaccord GenuityBlueprint Medicines Corporation (BPMC) Price Target Increased to $66.00 by Analysts at Canaccord Genuity
www.americanbankingnews.com - September 20 at 10:52 PM
Blueprint Medicines Corporation (BPMC) Director Daniel Lynch Sells 2,500 SharesBlueprint Medicines Corporation (BPMC) Director Daniel Lynch Sells 2,500 Shares
www.americanbankingnews.com - September 20 at 8:24 PM
Insider Selling: Blueprint Medicines Corporation (BPMC) Insider Sells 6,356 Shares of StockInsider Selling: Blueprint Medicines Corporation (BPMC) Insider Sells 6,356 Shares of Stock
www.americanbankingnews.com - September 20 at 7:58 PM
Blueprint Medicines Corporation (BPMC) Receives Buy Rating from Goldman Sachs Group, Inc. (The)Blueprint Medicines Corporation (BPMC) Receives Buy Rating from Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - September 20 at 2:38 PM
ETFs with exposure to Blueprint Medicines Corp. : September 19, 2017ETFs with exposure to Blueprint Medicines Corp. : September 19, 2017
finance.yahoo.com - September 19 at 9:47 PM
Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 5:04 PM
Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : September 12, 2017Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : September 12, 2017
finance.yahoo.com - September 12 at 5:11 PM
Blueprint Medicines Corporation (BPMC) Receives Buy Rating from Canaccord GenuityBlueprint Medicines Corporation (BPMC) Receives Buy Rating from Canaccord Genuity
www.americanbankingnews.com - September 11 at 9:32 PM
Blueprint Medicines Corporation (BPMC) Expected to Post Quarterly Sales of $5.16 MillionBlueprint Medicines Corporation (BPMC) Expected to Post Quarterly Sales of $5.16 Million
www.americanbankingnews.com - September 11 at 2:58 PM
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular CarcinomaBlueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma
finance.yahoo.com - September 10 at 4:18 PM
Blueprint Medicines Corporation (BPMC) Receives Average Recommendation of "Buy" from BrokeragesBlueprint Medicines Corporation (BPMC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 9 at 9:08 AM

Social Media

Financials

Chart

Blueprint Medicines Corporation (NASDAQ BPMC) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.